NBIX Share Price Performance

NBIX Community Fair Values

KA
kapirey
Community Contributor
Neurocrine Biosciences is set to achieve a 40x future PE ratio with a 17% revenue boost
Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u. Starts at approximately $21,338.71 USD for a monthly supply Ingrezza@ Ingrezza (valbenazine) As of July 2025 , the average pharmacy acquisition cost for Ingrezza capsules in the U.S. is approximately: $274.54 per capsule for the 60 mg and 80 mg strengths $250.16 per capsule for the 40 mg strength Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
US$244.80
FV
44.1% undervalued intrinsic discount
17.00%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
Updated narrative
AN
AnalystLowTarget
Consensus Narrative from 26 Analysts
Regulatory And Competitive Pressures Will Diminish Future Prospects
Key Takeaways Heavy dependence on INGREZZA and CRENESSITY exposes the company to regulatory, reimbursement, and competition risks that could threaten revenue growth and margins. Intensifying competition, payer consolidation, and potential R&D setbacks may erode market share, pricing power, and future earnings.
US$118.58
FV
15.3% overvalued intrinsic discount
8.72%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
3 months ago author updated this narrative
AN
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
Expanded Medicare Coverage And Trials Will Secure Patient Access
Key Takeaways Expansion in formulary coverage and Phase III programs strengthens future revenue potential through increased patient access and new product approvals. Solid cash reserves provide flexibility for growth investments, supporting long-term earnings and strategic business development initiatives.
US$163.76
FV
16.5% undervalued intrinsic discount
13.85%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
31users have followed this narrative
about 5 hours ago author updated this narrative
AN
AnalystHighTarget
Consensus Narrative from 26 Analysts
INGREZZA Expansion And Aging Demographics Will Unlock New Markets
Key Takeaways Growth is driven by expanding flagship products into new patient segments, increased healthcare coverage, and strong adoption of new therapies for neurological disorders. Diversified late-stage pipeline and strategic investments in R&D, marketing, and business development support long-term revenue, margin, and portfolio growth.
US$192.00
FV
28.8% undervalued intrinsic discount
18.95%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
7 days ago author updated this narrative

View all narratives

Recent NBIX News & Updates

No updates

Neurocrine Biosciences, Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): 3.09
Gross Margin: 63.91%
Net Profit Margin: 12.68%
Debt/Equity Ratio: 0%

View full report ›

Neurocrine Biosciences, Inc. Competitors

View more competitors

About NBIX

Founded: 1992
Employees: 1800
CEO: Kyle Gano
WebsiteView website: www.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

U.S. Market Performance

7 Days: 0.8%
3 Months: 15.1%
1 Year: 17.5%
Year to Date: 8.2%

Over the last 7 days, the market has remained flat, although notably the Energy sector gained 3.9% in that time. As for the longer term, the market has risen 17% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›

Who Will Win In The Age Of Agentic AI

Bailey Pemberton

July 2025

Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...

Last Week

Neurocrine Biosciences Stock Price

NBIX Share Price Performance

NBIX Community Fair Values

Neurocrine Biosciences is set to achieve a 40x future PE ratio with a 17% revenue boost

Regulatory And Competitive Pressures Will Diminish Future Prospects

Expanded Medicare Coverage And Trials Will Secure Patient Access

INGREZZA Expansion And Aging Demographics Will Unlock New Markets